Category: hitt

Genetic Therapy and the Industrial Uncertainties

Posted on by

Last week, EMA approved Strimvelis for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). It is the second genetic therapy approved by EMA after Glybera was cleared in 2012. The usual discussion goes around rarity, investment and pricing, which have been set at very high levels with a few unknowns on efficacy and long term safety. But it has to raise a parallel question, from the industrial and economic perspective.

Empowerment: isn’t it professionals time?

Posted on by

There is no discussion there is an increasing pressure over healthcare professionals. Recent times have just increased that feeling, and there may be some explanations to it. On the one side, the general public is increasing its requirements to the healthcare system, possibly poised by the press pressure of the apparent exciting results on healthcare. Not to say that it is ever more difficult to deliver significant improvements in healthcare, as major breakthroughs seem to have gone by. On the other side the financial pressure, where budgets have been cut, access is reduced or restricted and increasing scrutiny is posed on every euro spent.

hitt col·labora amb el Col·legi de Metges de Barcelona pel desenvolupament d’un estudi sobre malalties rares

Posted on by

El Col·legi de Metges de Barcelona (COMB) i Health Innovation Technology Transfer (HITT) han signat un acord de col·laboració per a la realització de l’estudi “La valoració del finançament de les malalties rares”, amb l’objectiu de disposar d’una eina que ajudi al desenvolupament de millors i més adequades polítiques de salut en aquest àmbit.

Unacceptable untreated Pain: time for action

Posted on by

I had yesterday a very interesting discussion about pain and pain treatment, why is it accepted to have a certain level of pain and what to do to improve untreated pain. In the United States, in 2011 the annual cost of untreated pain is reported to be between US$560–US$635 billion[1]. The discussions were about drugs, drug interactions, side effects, convenience, adherence, patient preferences and even about culture and religious beliefs.

Inscripciones abiertas al 1er Máster de Contratación Pública Sanitaria y Compliance

Posted on by

Este nuevo máster, que se inicia en enero 2016 y está coordinado por la consultora especialista en contratación pública sanitaria Tesera de Hospitalidad y la Sociedad Española de Directivos de la Salud (SEDISA), aporta un valor diferencial a los profesionales que centran su actividad profesional en este campo y necesitan una puesta al día con una visión de 360° eminentemente práctica.

This page uses cookies and other technologies so that we can improve your experience on our sites: More information about our cookies policy.